shortage of glp-1 receptor agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Receptor Agonist Market Size

Research Findings Selectivity Studies: Minimal cortisol elevation (unlike GHRP-6)

Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results

Not all peptides act alike, and understanding their biological tone - whether they promote or restrain blood vessel growth - is key when evaluating safety for each patient

About Glutathione Glutathione (GSH) is a tripeptide composed of glutamic acid, cysteine, and glycine that functions as the primary endogenous antioxidant in mammalian cells